

## Webinar on the current practice of disseminating additional risk minimisation measures (aRMM)

**March 19, 2026 – 12.00-13.30 CET**

The European DIS-aRMM study aims to gain a better understanding of the current practice of distributing aRMM to patients and healthcare professionals at national level, including any challenges encountered by different stakeholders. In the webinar we present the first results of the study and invite you to reflect on these results.

### What are additional risk minimisation measures (aRMMs)?

aRMMs help to reduce the risk of a medicine, such as preventing side effects or reducing their severity. aRMM materials provide both healthcare providers and patients with additional information about these risks. Examples of these materials include a prescriber or pharmacist checklist and a patient alert card.



### Who can join the webinar?

Stakeholders (e.g. marketing authorisation holders, authorities, healthcare professionals, professional organisations, patient organisations) **from all EU/EEA member states** interested in the process and key challenges of distributing aRMM materials. The webinar is free of charge.

### The DIS-aRMM study



To gain insight in the dissemination process from the perspective of different stakeholders, the study combined qualitative and quantitative methods. These methods included interviews with marketing authorisation holders, a focus group with authorities and questionnaires among patient organisations, patients and healthcare professionals. The study covered seven medicinal products (Aubagio, Eylea, Lemtrada, Lixiana, Xeljanz, valproate containing products and oral retinoids containing products) having different aRMM tools and is performed in six European countries (The Netherlands, Finland, Italy, Hungary, Lithuania and Romania). The results of the study will be included in a public report. The study is commissioned by the European Medicines Agency (EMA). EMA aims to use these results to improve the dissemination process for aRMM materials.

### Registration for the webinar

To register for the webinar or in case of any questions, please e-mail to:

Dr. Anne Brabers (principal investigator): [a.brabers@nivel.nl](mailto:a.brabers@nivel.nl).

After registration by e-mail, you will receive the webinar link.

*To foster a fruitful discussion, limited places are available during this webinar.*